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Background: There is paucity of data as to the results of the endoscopic approach in comparison to the golden
standard of nephro-ureterectomy in elective, low grade TCC, patients. Our purpose is to report our results of a
nephron sparing approach compared to nephro-ureterectomy in those patients.
Methods: From a retrospective data base we identified 25 patients and 23 patients who underwent a nephron
sparing ureterosocpic resection and nephro-reterectomy for low grade UT-TCC, respectively. The endoscopic
technique included endoscopic tumor biopsy followed by primary resection and/or fulguration. The nephron
sparing group was followed by bi-annual ureteroscopy and upper tract imaging, timely cystoscopy and urine
cytology collection. Data for overall and disease related mortality, bladder and ureteral TCC recurrence and renal
function are reported in both groups.
Results: Median follow - up time was 26 months. 11 (44%) patients developed bladder recurrence at a median
period of 9 months after initial ureteroscopy, compared to 9 (39%) in the NUx group (P < 0.05). Recurrent ureteral
low grade TCC was observed in 9 patients (median: 9 months). All were treated endoscopicaly successfully. Renal
function remained stable in the nephron sparing group. No disease related mortality was recorded in the
nephron-sparing group while one patient died of his disease following NUx.
Conclusions: Disease related mortality following a nephron sparing endoscopic approach or nephroureterectomy
for low grade upper tract TCC is excellent. However, the nephron sparing approach is associated with a relatively
high rate of ureteral and bladder recurrence. Therefore, a stringent follow-up protocol is required.
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The nephron-sparing approach for upper tract TCC was
traditionally reserved for patients with imperative indi-
cations such as solitary kidney, renal insufficiency or sig-
nificant co-morbidities [1,2]. With the advent of modern
endoscopic techniques the indications for a nephron
sparing endoscopic approach expanded. In the recent EAU
guidelines on urothelial carcinoma of the upper urinary
tract elective conservative management is indicated for* Correspondence: azikhof@gmail.com
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unless otherwise stated.unifocal, small, low grade, non-infiltrative tumors [3].
When choosing this approach, the main concern is
tumor progression or up-grading. However, only patients
with primary high-grade and non-Ta stage tumors were
found to be at significant risk of death from UT-TCC [3].
The concept of a nephron sparing approach was studied
widely in patients with RCC. Studies have shown that
decreased renal function is associated with significant
morbidity [4]. Therefore, partial nephrectomy is now the
new standard of care when indicated. The same concept is
gaining acceptance in UT-TCC. However, there is paucity
of data comparing the oncological outcome of the neph-
ron sparing approach in comparison to the gold standardal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cuff. In the current study we have conducted a retrospect-
ive comparison of the midterm follow-up results in patients
with low grade UT-TCC treated by nephron-ureterectomy
or an endoscopic resection.
Methods
A systemic review for nephron-sparing management for
patient with upper tract TCC was collected out of an
institutional database including over 2700 ureteroscopic
surgery performed between the years 2000–2010 in our
institute. Patient with high grade upper tract TCC were
excluded. Over 150 nephro-ureterectomy surgery were
performed in the same period of time, 22 of them for
upper tract low grade TCC.
Patients
25 (0.9%) patients were identified in our database with low
grade UT-TCC that was managed by endoscopic approach
(group 1), compared to 22 patients who had nephro-ure-
terectomy due to endoscopically un-resectable (group 2)
low grade UT-TCC. All patients in group 1 had tu-
mors ≤1.5 cm that had papillary ureteroscopic appearance
and could be completely resected.
Endoscopic surgical technique
Renal and proximal ureter tumors were resected and ab-
lated using a combination of holmium laser energy and
monopolar electrocautry with a 1.9 FR bugbee electrode.
For distal ureter tumors a 10.5 Fr. ureteroresectoscope
(storz©) was preferentially utilized. A pathological speci-
men was obtained prior to resection during ureteroscopy.
Nephroureterectomy was performed open or laparo-
scopic with open distal ureter release and formal bladder
cuff excision and bladder two-layer closure.
Follow-up protocol
After primary resection, all patients were submitted to a
pre-planned cystoscopy and urine cytology every 3 months
for three years. Ureteroscopy was performed 3 months
after initial resection and every 6 months thereafter if noTable 1 Group data
Endoscopic resection grou
Median age at diagnosis, months (range), 64 (42–85)
Median follow up, months (range) 26 (12–126)
Primary tumor location (%)
Kidney + renal pelvis 6 (24%)
Proximal ureter 3 (12%)
Distal ureter 17 (68%)
Pre OP creatinine clearance (MDRD) 66
Post OP creatinine clearance (MDRD) 62recurrence was noted. CT urography or intravenous pyel-
ography was performed every 6 months alternating with
follow-up ureteroscopy. Kidney GFR was assessed using
MDRD calculation once a year [5]. All participants have
expressed their Informed consent, and the study was
approved by the local (Rabin Medical Center) ethics
(Helsinki) committee.
Statistical analysis
Age and creatinine clearance were compared using
student's T-test. Bladder cancer free probability was ana-
lyzed using log rank analysis.
Results
Median patient age at diagnosis was 64 years (range: 42–
85) and 76 years (50–89) in the endoscopic resection group
(group 1) and NUx group (group 2), respectively (p < 0.05).
Primary diagnostic ureteroscopy identified Ta low grade
TCC in 21 patients and non-conclusive result (due to lack
of proper biopsy tissue) in four patients in group 1. Median
follow up time was 26 months (range: 12–126) and
57 months (range: 12–149), respectively (Table 1). Patient
data and primary location of the upper tract tumor is also
shown in Table 1. Median follow time up after primary
resection was 26 months (range: 12–126) and 57 months
(range: 12–149) in groups 1 and 2, respectively.
Bladder TCC free probability is illustrated in Figure 1.
In group 1, 11 patients (44%) developed bladder recur-
rence at a median period of 9 months (range: 2–43). Four
(16%) patients had more than one recurrence, compared
to 9 (39%) patients in group 2 (median time 13 months,
range: 5–34). Three bladder recurrences were detected by
positive cytology during follow up and Four (16%) had
more than one bladder recurrence in group 1. All bladder
recurrences were non-muscle invasive and were managed
successfully by trans-urethral complete resection.
Ureteral TCC free probability is illustrated in Figure 2.
Recurrent ureteral low grade TCC was observed in
9 patients (median: 9 months, range: 3–36) in group 1.
All were re-treated successfully by a second endoscopic
procedure. No case of pathological ureteral TCC up-p (N = 25) Nephroureterectomy group (N = 22) P value







Figure 1 Bladder recurrence.
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period.
Renal function, as calculated according to MDRD for-
mula, remained stable in all patients in group 1 during
follow-up, including six patients who presented with
stage 3 chronic kidney disease (median eGFR 53 ml/min/
1.73 m2) (Table 1).
Overall survival rates are illustrated in Figure 3.
No disease related mortality was observed in group 1.
In group 2, one patient died of muscle invasive bladderFigure 2 Ureteral recurrence.TCC ten years after initial UT-TCC diagnosis. Seven pa-
tients (28%) in group 1 died of non-TCC related causes
(median time: 20 months, range: 12–55), compared to 4
(17%) in group 2 (median time: 50, range: 15–60 months).
Discussion
Traditionally, a nephron-sparing endoscopic approach to
UT-TCC was reserved for imperative indications. Recently
though, this has been challenged with endoscopy applied
more frequently in elective cases. However, as UT-TCC
Figure 3 Overall survival.
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scopic therapy is accordingly limited. A Cochrane review
of the surgical management of UT-TCC in 2011 con-
cluded that there is no high quality evidence available
to determine the best surgical management, although
current data, albeit limited, suggests a similar oncologic out-
come when endoscopy is compared to an open approach
[6]. Our study adds to the relatively small number of
comparative studies focusing on patients with low grade
UT-TCC, and furthers the growing understanding that
nephroureterectomy may in fact be overtreatment. In a
similar finding to Grasso et al. [7], our results indicate that
patients' safety and disease-related mortality are not hin-
dered by a nephron-sparing approach. Whereas there is
little risk of disease progression and associated mortality
for low-grade UT-TCC, the risk of ureteral and bladder
recurrence is significant, and is absolutely dependent on a
stringent follow-up protocol. In two separate reports of
endoscopic treatment of low-grade UT-TCC with medium
to long-term follow-up, upper tract recurrence ranged
between 74% and 84%, with cancer-specific survival of
100% [8,9]. In a report of medium-term follow-up of
low and high-grade UT-TCC resected endoscopically,
Thompson et al. revealed ureter and bladder recurrence
in 55% and 45% respectively, with high-grade and non-Ta
staging associated with greater mortality [10]. Similarly, in
their review, Cutress et al. identified a pooled recurrence
rate of 52% following endoscopic therapy for UT-TCC,
with a grade-dependent trend. Further, size (>2 cm), prior
history of bladder tumor, and greater than three previousbladder tumor resections were associated with UT recur-
rence [11]. Our results suggest similar bladder and ureter
recurrence rates with excellent disease-related mortality,
possibly due to our careful patient selection (tumor size up
to 1.5 cm and papillary low-grade appearance at primary
resection). As with all other related studies, this study is
limited by its retrospective nature as well as relatively long
treatment period (ten years), both a result of the rarity of
the disease. Nevertheless, it would seem almost impossible
to prospectively recruit patients for a randomized study.
Conclusion
Nephron -sparing endoscopic approach for low grade
upper tract TCC in well selected cases is associated with
good cancer free progression results and stable renal
function and could be considered in patients with nor-
mal contra lateral kidney. Patient's compliance is essen-
tial due to the rigorous follow-up protocol required.
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